Zoetis Inc. $ZTS Shares Newly Acquired by DMKC Advisory Services LLC

DMKC Advisory Services LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 45,335 shares of the company’s stock, valued at approximately $3,166,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Flossbach Von Storch SE bought a new stake in shares of Zoetis in the 2nd quarter valued at about $302,601,000. BlackRock Inc. raised its position in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Ruane Cunniff & Goldfarb L.P. acquired a new stake in shares of Zoetis in the 1st quarter valued at approximately $286,660,000. Southpoint Capital Advisors LP boosted its stake in Zoetis by 340.0% during the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock worth $260,062,000 after acquiring an additional 1,700,000 shares during the last quarter. Finally, Carmignac Gestion bought a new position in Zoetis during the 2nd quarter worth approximately $113,230,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Citigroup decreased their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. BTIG Research dropped coverage on shares of Zoetis in a report on Friday, October 30th. They issued a “buy” rating and a $200.00 target price on the stock. UBS Group lifted their price target on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 27th. TD Cowen reduced their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Finally, William Blair lowered shares of Zoetis from an “outperform” rating to a “market perform” rating in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $101.25.

Zoetis Trading Up 3.5%

NYSE ZTS opened at $82.17 on Tuesday. The firm has a market cap of $33.95 billion, a P/E ratio of 13.97, a P/E/G ratio of 1.32 and a beta of 0.67. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock’s 50-day moving average is $75.77 and its 200-day moving average is $92.39. Zoetis Inc. has a one year low of $68.77 and a one year high of $132.49.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.24. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the business posted $1.70 EPS. Zoetis’s revenue for the quarter was down 1.3% on a year-over-year basis. Sell-side analysts anticipate that Zoetis Inc. will post 6.25 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is 36.05%.

Zoetis Company Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.